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Mycosis fungoides (MF) is the most frequent mani-
festation of cutaneous T cell lymphoma but its cause
and pathophysiology remain unclear. Because pro-
gression of lesions is characteristically slow, we
hypothesized that mycosis fungoides originates from
an accumulation of lymphocytes due to defective
apoptosis of skin homing T lymphocytes. In this
study, we investigate possible alterations of three
molecules regulating apoptosis, i.e., Fas antigen,
Bax, and p53, at the genomic level in skin lesions
from 44 patients with MF, as Fas mediates one of
two major pathways for apoptosis of activated T
cells. Fas mutations were found in six patients using
a polymerase chain reaction and single-strand con-
formational polymorphism method followed by
cloning and sequencing of abnormal polymerase
chain reaction products. The mutations predict for
defective transmission of the death signal in three
cases. Immunohistochemistry demonstrated the lack
of Fas protein expression on dermal lymphocytes in
one case with Fas gene mutation predicting for a
truncated death domain, whereas Fas protein was
expressed by dermal lymphocytes in the other inves-
tigated cases. By contrast, no mutations of Bax or
p53 were found, whereas immunohistochemistry
demonstrated increased p53 expression in the nucleus
of basal keratinocytes above the neoplastic in®ltrate
in some MF cases. These results support the hypoth-
esis that Fas defects may play a role in the pathogen-
esis of MF. Key words: apoptosis/ cutaneous T cell
lymphoma/ physiopathology. J Invest Dermatol 118:949±
956, 2002
M
ycosis fungoides (MF) is the most frequent
primary cutaneous T cell lymphoma character-
ized by erythematous patches evolving to in®l-
trated plaques, nodules and less frequently tumors
and erythroderma. The main histologic feature of
MF is a super®cial dermal, often epidermotropic, in®ltrate
composed of CD4+ helper T lymphocytes expressing cutaneous
lymphocyte antigen CLA (Picker et al, 1990). The pathogenesis of
MF is poorly understood as viral (mainly EBV) and retroviral
theories have not been substantiated to date (Hall et al, 1991;
Pancake et al, 1995; Angel et al, 1996; Lessin et al, 1996; Jumbou et
al, 1997; Wood et al, 1997), whereas chronic antigenic stimulation
remains possible (Wood, 1995). Molecular and genetic studies
focused mainly on p53, bcl-3, NFKB2/lyt-10, and Tal-1 are sparse
in MF and have not demonstrated consistent genetic alterations
(Beylot-Barry et al, 1995; Garatti et al, 1995; Lauritzen et al, 1995;
Li et al, 1998), especially in the early stages. In particular, mutations
of tumor suppressor gene p53 have been detected in only one case
of plaque stage MF (van Haselen et al, 1997), whereas it seems more
frequent in advanced, tumor cases but without high speci®city
(McGregor et al, 1999). Recent studies have shown hypermethyla-
tion and allelic loss, but no point mutation of the p16INKa gene in
MF (Navas et al, 2000), and loss of heterozygosity on 10q with
possible homozygous deletion of the tumor suppressor gene PTEN,
mainly in advanced cases of MF (Scarisbrick et al, 2000).
An alternative hypothesis could consider early MF to develop
from an accumulation of CLA+ T lymphocytes rather than a
neoplastic disease. Assessment of apoptosis in lymphoid cells of MF
lesions had been done in only a small number of cases using the
TUNEL method. The results were equivocal and no de®nite
conclusion could be made (Kikuchi and Nishikawa, 1997). An
initial accumulation of T lymphocytes would explain the usually
protracted indolent course and the limited atypical features
observed in early MF. According to this hypothesis, the initial
event might be related to defective apoptosis occurring in a subset
of activated T cells expressing CLA. Alterations of four major
regulators of apoptosis, p53, Fas, bax, and bcl-2, have been reported
in some hematologic malignancies. Speci®cally, mutations of Fas,
one of the main regulators of postactivation apoptosis (Nagata,
1997), are present in non-Hodgkin's lymphomas (Gronbaek et al,
1998), HTLV-1-induced acute T cell leukemia of adults (Tamiya et
al, 1998), acute lymphoblastic leukemia of childhood (Beltinger et
al, 1998), and multiple myeloma (Landowski et al, 1997), whereas
mutations of the pro-apoptotic gene bax with potential loss of
function have been reported in non-Hodgkin's lymphomas
(Meijerink et al, 1995; Brimmell et al, 1998; Meijerink et al,
1998; Peng et al, 1998; Gutierrez et al, 1999; Gaidano et al, 2000;
Inoue et al, 2000; Miyauchi et al, 2000). Bax expression appears
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decreased in low-grade lymphoid malignancies compared with
more aggressive diseases, which supports impaired bax-mediated
apoptosis as a basic mechanism in low-grade lymphomas such as
MF (Soini et al, 1998; Wheaton et al, 1998; Camillieri-Broet et al,
2000). There are similarities in the slow clinical evolution and
outcome of MF and follicular nodal lymphoma, a condition clearly
related to overexpression of antiapoptotic bcl-2 (Korsmeyer, 1999;
Stamatopoulos et al, 2000). Finally, a dominant autosomal
autoimmune lymphoproliferative syndrome (ALPS), characterized
by prominent accumulation of lymphocytes in lymphoid organs,
has been recently described and attributed in most cases to
dominant negative germline mutations in the Fas gene (Fisher et al,
1995; Rieux-Laucat et al, 1995; Drappa et al, 1996; Bettinardi et al,
1997; Dianzani et al, 1997; Sneller et al, 1997).
Our hypothesis has led us to search for alterations in genes
regulating apoptosis of T cells, namely fas, Bax, and p53 in MF. We
examined the nine exons of the translated part of the Fas gene, the
six exons of the coding part of the bax gene, and exons 5±9 of the
p53 gene by exon-speci®c polymerase chain reaction (PCR) and
single-strand conformational polymorphism (SSCP) analysis, along
with Fas, Bax, and p53 expression by immunohistochemistry in
cutaneous lesions of 44 MF patients.
MATERIAL AND METHODS
Tissues and patients Forty-four cutaneous biopsies from 44 patients
with MF were selected randomly on the basis of available paraf®n blocks
and frozen tissues. In all cases, the diagnosis of MF was con®rmed by
clinical, histologic, and, in all but three cases, immunophenotypic criteria.
Biopsies were performed on patches (24 cases), plaques (17 cases), and
tumors (three cases). Neoplastic cells with convoluted nuclei resembling
Sezary cells were present with some degree of epidermotropism in each
case. Tissues used for DNA extraction were either snap-frozen or paraf®n-
embedded. Paraf®n-embedded biopsies from eight patients with lichen
planus were used as controls for the molecular study of Fas, Bax, and p53,
and for Bax and Fas immunohistochemistry. Additional frozen samples
from 10 patients with eczema were used as a negative control group for
p53 immunostaining.
Genomic DNA extraction Because the only available tissues for
some patients were formalin-®xed, paraf®n-embedded samples, we used
genomic DNA instead of cDNA for all samples. To limit the
background of normal keratinocyte DNA, we performed microdissection
in 29 of 44 MF samples prior to DNA extraction, carefully removing by
hand with a 30 gauge needle the upper part of the dermal in®ltrate
under microscopic control on 25 mm thick tissue sections. This
procedure eliminated most of the epidermal background and improved
detection of the T cell clone probably by an increase in DNA from
neoplastic cells (data not shown, manuscript submitted). Genomic DNA
was extracted from both snap-frozen and paraf®n-embedded tissues.
Paraf®n slides were dewaxed and submitted to overnight digestion with
0.1 mg proteinase K at 37°C. After desalting with 0.5 vol of NaCl 5 M
and centrifugation, genomic DNA in clear supernatant was precipated
with two volumes absolute ethanol. Pelleted DNA was washed with 70%
ethanol, dried, dissolved in 50 ml Tris 10 mM, pH 7.6, EDTA 1 mM,
pH 8 and stored at 4°C until further use.
PCR ampli®cation Primer pairs were designed to amplify the
coding region of the Fas gene (i.e., exons 1±9), according to previous
reports (Beltinger et al, 1998) or with the help of Primer 3 software
(Whitehead Institute for Biomedical Research of the Massachussets
Institute of Technology, Cambridge, MA, web site: http://
www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi). The entire
coding region of the bax gene (i.e., exons 1±6) and exons 5±9 of the
p53 gene were ampli®ed according to previous reports. Because of the
length of exon 5 of p53, it was ampli®ed with two different sets of
primers leading to two overlapping amplicons. Detailed sequences of
primers and the size of the expected products are showed in Tables I, II
and III. Radioactive PCR was performed on a Perkin-Elmer-Cetus
N801-0150 DNA Thermal Cycler, with 100 ng of genomic DNA, 250±
50 nmol per liter of each primer, 2.5 mCi of 32PdCTP and Ready-to-Go
PCR beads (Pharmacia Biotech, Piscataway, NJ) 200 mmol per liter each
of dATP, dCTP, dTTP, and dGTP; 50 mmol KCl per liter; 1.5 mmol
MgCl2 per liter; 10 mmol Tris-Hcl pH 9.0 per liter; 1.5 units of Taq
DNA polymerase with a ®nal volume of 25 ml. The samples were
denatured at 95°C for 5 min then ampli®ed for 35 cycles consisting of 1
min at 95°C, 1 min at a temperature range of 58±65°C, depending on
the primer pair and 2 min at 72°C, followed by a ®nal extension
segment of 10 min at 72°C. Quality of the PCR was controlled by
migration of a sample ampli®ed without radioactive nucleotide in a 2%
agarose gel.
Table I. Primers used for PCR-SSCP analysis of Fas
Primers Sequence
Size of the
product
1-F 5¢-GGAAGCTCTTTCACTTCGGA-3¢ 116 bp
1-R 5¢CTAAGACGGGGTAAGCCTCC-3¢
2-F 5¢-GTGGGTTACACTTCTTTACCACGTTGC-3¢ 216 bp
2-R 5¢-CATGATTACTATGTGCTACTCCTAACTG-3¢
3-F 5¢-CCGTGTCCTGTTCAAACACTT-3¢ 220 bp
3-R 5¢-CCAAGATTGGCCTCTTTCAA-3¢
4-R 5¢-CTGCTTATAATTAGCCGCGA-3¢ 228 bp
4-F 5¢-ACTTCCCTAGGAAAATGATAACTCT-3¢
5-F 5¢-TGCCAGGCTTTTGAATTTCT-3¢ 161 bp
5-R 5¢-TCACATCTTTCCCTGGGGTT-3¢
6-F 5¢-CAATCACTCTTGATTAGTAGAAAGTCC-3¢ 210 bp
6-R 5¢-TTGTGAACTACTTCCCCCAAG-3¢
7-F 5¢-CATGCATTCTACAAGGCTGAG-3¢ 178 bp
7-R 5¢-TTTTCTTTTCAAGGAAAGCTGAT-3¢
8-F 5¢-TTTATTTGTCTTTCTCTGCTTCCA-3¢ 123 bp
8-R 5¢-GGCCTATTACTCTAAAGGATGCC-3¢
9±1F 5¢-TGGGAATTTCATTTAGAAAAACAA-3¢ 261 bp
9±1R 5¢-TGTCATACGCTTCTTTCTTTCC-3¢
9±2F 5¢-CAATGTCCAAGACACAGCAGA-3¢ 246 bp
9±2R 5¢-TACTCAGAACTGAATTTGTTGTT-3¢
Table II. Primers used for PCR-SSCP analysis of Bax
Primer Sequence
Size of the
product
1F 5¢-CGTTCAGCGGGGCTCTCA-3¢ 207 bp
1R 5¢-CAGGCCGGTAGGAAGGAT-3¢
2±3F 5¢-CCCCTAGAACCCAAGAGTC-3¢ 400 bp
2±3R 5¢-GGCTGAGAGTCCTGTGTCC-3¢
4F 5¢-TCTCCTGCAGGATGATTGC-3¢ 209 bp
4R 5¢-TCCCCAGGTCCTCACAGAT-3¢
5F 5¢-CAGGCAGTGGGGACAAGGTT-3¢ 192 bp
5R 5¢GCGGTGGTGGGGGTGAGGAG-3¢
6F 5¢-CCCCTGGCCGAGTCACTGAA-3¢ 237 bp
6R 5¢-AATGCCCATGTCCCCCAATC-3¢
Table III. Primers used for PCR-SSCP analysis of p53
Primer Sequence
Size of the
product
5F 5¢-GCCGTGTTCCAGTTGCTTTATC-3¢ 186 bp
5R 5¢-GTAGATGGCCATGGCGCGGACG-3¢
5¢F 5¢-GTGGATTCCACACCCCCGCCCGG-3¢ 192 bp
5¢R 5¢-TCAGTGAGGAATCAGAGGCC-3¢
6F 5¢-CTGGAGAGACGACAGGGCTG-3¢ 236 bp
6R 5¢-GCCACTGACAACCACCCTTA-3¢
7F 5¢-CCTCATCTTGGGCCTGTGTT-3¢ 202 bp
7R 5¢-TCAGCGGCAAGCAGAGGCTG-3¢
8±9F 5¢-AGGACCTGATTTCCTTACTTG-3¢ 390 bp
8±9R 5¢-CTTTCCACTTGATAAGAGGTC-3¢
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Single-strand conformation polymorphism analysis Five
microliters of radiolabeled ampli®ed DNA was diluted in 5 ml of loading
buffer (95% formamide, 5% EDTA 0.5 M pH 8, 0.025% bromophenol
blue, 0.025 xylene cyanol blue), denatured at 95°C for 10 min,
immediately cooled on ice for 5 min and loaded onto a nondenaturing
polyacrylamide gel. Gels consisted of 0.5 3 glycerol tolerant buffer
(Amersham Life Science, Arlington Heights, IL), 5% glycerol and
acrylamide (29:1 bi) 4±6.5% according to the size of the PCR product.
Electrophoresis was carried out with 0.6 watts for 18±20 h at room
temperature. Autoradiography was performed at ±80°C overnight or
longer if necessary. When band shifts were observed, a second round of
radioactive PCR-SSCP was carried out for con®rmation. Additional
bands were then excised from the gel and DNA was extracted and
puri®ed using the QUIAEX II gel extraction kit (Quiagen, Santa Clara,
CA). Extracted DNA was then re-ampli®ed for 35 cycles with the same
primer pair.
Cloning and sequencing analysis PCR products from the previous
step were cloned using the TOPO-TA cloning kit (Invitrogen, La Jolla,
CA). The recombinant plasmids were extracted with the QUIA
Miniprep Spin kit (Quiagen) and sequenced with an automated Perkin-
Elmer ABI Prism 377 XL sequencer using the Prism DNA Sequencing
Analysis version 3.0 software and dye terminators. Three to ®ve clones
for each shifted band were selected for sequencing. The obtained
sequences were analyzed and aligned using the Blast software from the
National Cancer Institute, National Institute for Health, Bethesda, MD
(website: http://www.ncbi.nlm.nih.gov/BLAST/).
Immunohistochemistry Five micrometer thick sections were cut
from paraf®n-embedded MF and lichen planus (Bax, Fas) or frozen
tissues of MF and eczema (p53). For Bax and Fas immunostaining, the
slides were baked at 60°C for 45 min, dewaxed and submitted to an
antigen retrieval procedure in a 10 mmol sodium monochlorydrate per
liter bath heated to 95°C for 12 min and then cooled for at least 30 min.
Fas and Bax immunohistochemistry were carried out with a murine
monoclonal anti-Fas antibody (Clone APO-1; Dako, Carpenteria, CA)
diluted at 1:100 and a murine polyclonal anti-Bax antibody (Dako)
diluted at 1:100, using the tyramine-ampli®ed detection CSA kit (Dako)
in both cases. Slides were counterstained with hematoxylin, dehydrated
with ethanol, washed in xylene, and mounted with covering glasses. p53
immunostaining was performed on OCT embedded frozen tissue
sections from MF and eczema with three different primary antibodies:
two monoclonal antibodies (DO7 (Novocastra Laboratories, Newcastle
upon Tyne, U.K.) and 1801 (Oncogene Science)) and one polyclonal
antibody (CM1, Novocastra Laboratories, U.K.). These three antibodies
recognize both wild-type and mutated versions of the protein. They
were used at a 1/50 dilution in PBS/0.5% BSA and revealed with a
streptavidin-biotin-peroxidase method (kit Immunstain, DPC). A
Xeroderma Pigmentosum-induced epidermoid carcinoma with known
mutation-induced p53 overexpression was used as a positive control. In
all cases, negative controls included slides where the primary antibody
was replaced by its diluent.
No loss of heterozygosity (LOH) assay was performed due to the
unavailability of normal tissues for most patients and because of the
heterogeneity of the dermal in®ltrate in which neoplastic cells were often
less numerous than normal or reactive cells.
RESULTS
Molecular analysis All specimens provided adequate genomic
DNA for PCR. In Fas gene analysis, two rounds of radioactive
PCR-SSCP analysis con®rmed mobility shifts of exons 2, 3, 4, 7,
and 8 in seven patients (Fig 1). No patient with lichen planus
showed any mobility shifts with the nine primer pairs. The results
of the sequencing procedures were considered valid only when at
least two clones displayed the same result, and are summarized in
Table IV. Sequence analysis revealed point mutations of the Fas
gene coding sequence in six patients. Patient 1 displayed a C to T
transition at bp 313 (exon 2) with subsequent substitution of THR
to ILE at amino acid 40 (CDR1) (Fig 2a). Patient 2 had a G to A
transition at bp 448 (exon 3) with resulting substitution of CYS by
TYR at amino acid 85 (junction CDR1-CDR2) (Fig 2b). Patient
3 showed an A to G transition at bp 535 (exon 4), leading to a
substitution of GLU to GLY at amino acid 114 (CDR2). In patient
4, an insertion of a G at bp 765 (exon 7) resulted in a frame shift and
appearance of a premature stop codon at amino acid 211 with a
truncated molecule lacking the death domain. Patient 5 had a
microdeletion of a G at bp 846 (exon 8) resulting in a frame shift
with premature stop codon at amino acid 222 with a predicted
molecule lacking the death domain. The sample from patient 6
displayed an A to C transversion at bp 849 (exon 8) with a
replacement of THR by PRO at amino acid 219. Patient 7 showed
a mobility shift in the exon 3 corresponding to heterozygosity for
the previously described polymorphism at bp 416 (A to G) (Fiucci
and Ruberti, 1994).
PCR-SSCP analysis on both bax and p53 genes was carried out
on 41 samples from MF and eight biopsies from lichen planus. The
migration pattern of the six coding exons of bax gene displayed no
abnormal band in any of the samples. An additional band was
present in one MF sample only within exon 5 of the p53 gene,
con®rmed by a second round of PCR-SSCP. Cloning and
Figure 1. PCR-SSCP analysis of Fas antigen in MF patients skin
samples. 32P-labeled PCR products from exon 8 are separated on a 7%
nondenaturing polyacrylamide gel. Lanes 1±4 show a normal pattern of
two bands in four patients. The arrow in lane 5 indicates an abnormal
band excised for cloning and sequence analysis detected in the lesion of
patient 5.
Table IV. Summary of clinical, histologic, and molecular data of the six MF patients with Fas gene alterations
Patient Clinical data Histopathology Sequence changesa Amino acid changes
1 Patches and plaques Upper dermal in®ltrate with
epidermotropism
C313T THR 40 ILE
2 Plaques Upper dermal in®ltrate G448A CYS 85 TYR
3 Patches and plaques Upper dermal in®ltrate with
epidermotropism
A535G GLU 114 GLY
4 Rapidly progressing tumors Dense overall dermal in®ltrate Insertion G 765
stop at codon 211
Frameshift with premature
codon
5 Patches Upper dermal in®ltrate Deletion G 846
stop at codon 222
Frameshift with premature
codon
6 Plaques Upper dermal in®ltrate with
epidermotropism
A849C THR 219 PRO
aExpressed in cDNA nucleotide number according to Itoh et al (1991).
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sequence analysis revealed a C to T transition at bp 596 of cDNA
without any effect on the primary sequence of the protein and
probably corresponding to a genetic polymorphism.
Immunohistochemistry Immunohistochemical analysis of Fas
was performed in 19 of 44 MF and in ®ve lichen planus cases. All
MF cases displayed moderate to strong staining of basal, and to a
lesser extent, of suprabasal layer keratinocytes in the epidermis and
consistently strong staining of endothelial cells and sweat glands.
Lymphocytes of the dermal in®ltrate were faintly to moderately
stained in all cases but one (including two patients with missense
mutations of the Fas gene). Indeed, the patient displaying a
mutation in exon 8 and subsequent frame shift with predicted
disappearance of the death domain showed no staining of atypical
lymphocytes, whereas the epidermis displayed the usual pattern
(Fig 3a). In most stained cells, a granular intracytoplasmic pattern
associated with a membrane stain was observed. All lichen planus
cases displayed stronger staining of the epidermis and the dermal
in¯ammatory in®ltrate than MF patients (Fig 3b).
Bax expression was studied in 13 MF and eight lichen planus
cases. In all cases, clear cytoplasmic staining of the dermal lymphoid
cells was obtained with a similar intensity in MF and lichen planus
(Fig 4). Immunostaining for p53 was carried out on 12 cryostat
sectioned biopsies of MF and 10 of eczema with each of three
antibodies. No staining was obtained in epidermis or in dermal
in®ltrate for eczema samples. Conversely, two cases of MF showed
nuclear staining of some dermal lymphoid cells with a least two
antibodies; some of the stained cells appearing as cytologicaly
atypical (Fig 5a). Furthermore, ®ve of 12 MF patients (three patch-
stage and two plaque-stage patients) consistently displayed nuclear
staining of basal keratinocytes above the dermal in®ltrate with at
least one antibody, but in none of these ®ve cases was there any
staining of dermal neoplastic lymphocytes (Fig 5b, c). Negative and
positive controls displayed the expected results.
DISCUSSION
In this paper, we describe the presence of six point mutations of the
coding sequence of the Fas gene in six of 44 patients with MF
investigated (13%). The expression of Fas protein in lymphoid cells
of the dermal in®ltrate was absent in one case with a frame shift
mutation, predicting for the disappearance of the death domain of
the mutated allele. The low percentage of Fas mutations detected in
MF must be interpreted in the context of limitations of the PCR-
SSCP method used when genomic DNA is derived from a
heterogeneous tissue containing both tumor and numerous reactive
cells (Shef®eld et al, 1993; Thor Straten et al, 1998); the percentage
of tumor cells may be below the threshold of detection of PCR-
SSCP. The functional signi®cance of the identi®ed mutations of Fas
in these cases of MF is variable. The two cases with frameshift and
premature stop codons, theoretically resulting in the disappearance
of the death domain, are likely to have important functional
consequences as this part of the molecule is crucial for transmission
of the death signal (Cascino et al, 1996). A dominant negative effect
of heterozygous death domain alterations, perhaps linked to the
trimeric nature of the membrane receptor, is very likely in ALPS
(Takahashi et al, 1994) and is suspected in plasma cell myeloma
(Landowski et al, 1997) and non-Hodgkin lymphoma (Gronbaek et
al, 1998). The lack of expression of Fas in the dermal lymphoid cells
in one of the two cases with the possible disappearance of the death
domain also supports the hypothesis of signi®cant impairment of
the Fas function, the truncation of the molecule possibly impairing
formation of the membrane trimer. The signi®cance of the
missense mutations is less clear as they do not seem to be associated
with loss of expression of the protein; however, one of them
(G448A) leads to a nonconservative change of amino acid 85, very
close to the two amino acids crucial for ef®cient binding of Fas-
ligand (Starling et al, 1997), and may be functionally important. The
signi®cance of the three remaining missense mutations is unknown
but it must be emphasized that two of them are nonconservative.
No relationship between the clinical or histologic pattern of
lesions and the pro®le of mutations could be established, given the
small number of cases with identi®ed mutations. Most patients were
of the usual type with chronic, patch, and plaque-type lesions,
although one patient with a frame shift mutation had rapidly
progressing tumors with a heavy dermal in®ltrate, although without
large cells. This presentation does not ®t the model of slow
lymphocyte accumulation, but subsequent mutations involving key
genes may have occurred.
We hypothesize that defective apoptosis of chronically antigen-
stimulated T cells is involved in some cases of MF through
alterations of regulators of this apoptotic process, like the Fas-Fas
Ligand system or the proapoptotic molecules Bax or p53, a theory
of interest in CTCL in general (Meech et al, 2001). This hypothesis
is based upon the following clinical and experimental observations.
(1) The usual indolent course of the disease, consistent with an
accumulation rather than a proliferation of lymphocytes, similar to
follicular lymphomas where there is over-expression of apoptosis-
inhibiting gene bcl-2 (Korsmeyer, 1999). (2) A hypothesis
considering an etiologic relationship between chronic T cell
activation in the skin and MF (Wood, 1995). (3) It has been
recently reported that the Fas/Fas ligand system is likely to play a
crucial role in the downregulation of T cell activation in contact
dermatitis (Orteu et al, 1998). (4) Ultraviolet light therapy, a
common treatment in the ®rst stages of MF, seems to act by
Figure 2. Sequence analysis of exon 2 (a) and
3 (b) -speci®c PCR product extracted from the
additional band in SSCP gel from patients 1 and
2, respectively: point mutation (arrows) in position
313 with C to T transition (a) and 448 with G to
A transition (b); normal sequences are shown
below.
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upregulating T cell apoptosis in the skin rather than reducing the
rate of T cell proliferation (Miracco et al, 1997), and is likely to
involve Fas/Fas ligand interactions (Caricchio et al, 1998). (5)
Mutations of Fas or Bax have been reported in other human
hematologic malignancies, especially multiple myeloma
(Landowski et al, 1997), which is characterized in the initial
indolent phase by an accumulation of slowly proliferating plasma
cells, and by low-grade non-Hodgkin lymphoma (Gronbaeck et al,
1998). (6) Demonstration of a signi®cant decrease of Fas expression
on peripheral blood CD4+ lymphocytes in CTCL compared with
benign lymphocytes (Dereure et al, 2000) and on neoplastic cells in
aggressive types of CTCL (Zoi-Toli et al, 2000), data which overall
suggest that loss of Fas receptor expression may be involved in the
pathogenesis or progression of some types of CTCL. (7) The
presence in peripheral blood of an abnormal population of atypical
lymphoid cells that lack Fas expression in some cases of so-called
primitive hypereosinophilic syndrome, a condition that can be
related to a secretion of interleukin-5 by an abnormal lymphoid
clone that can evolve into a peripheral T cell lymphoma (Simon et
al, 1999). By contrast, expression of Fas by neoplastic cells did not
seem to be altered in some cases of MF and SS in a recent
immunohistochemistry study (Kamarashev et al, 1998).
Bax, the pro-apoptotic partner of bcl-2, has been found mutated
in some human hematologic malignancies and colonic cancers.
These mutations often involve a crucial tract of eight guanines, the
deletion or insertion of one guanine leading to a frame shift, a
premature stop codon, and ®nally to a truncated inactive molecule,
no longer detectable by immunohistochemistry (Brimmell et al,
1998; Meijerink et al, 1998). In other cases, the mutations result in
alterations that prevent the protein from forming ef®cient hetero-
dimers with its partner bcl-2, with an imbalance between anti- and
pro-apoptotic in¯uences as a result (Meijerink et al, 1998). Analysis
of Bax has not been reported previously in MF. Our study shows
that Bax expression is conserved in the lymphoid dermal in®ltrate
and that no mutation is detected by PCR-SSCP. Regardless of the
limitations of sensitivity of the SSCP method (Shef®eld et al, 1993),
these ®ndings do not support a role for Bax alterations in MF. It can
be pointed out that earlier studies of bcl-2 in search of gene
alterations and overexpression, although rare and inconclusive, do
not favor a role of bcl-2 alterations in the pathogenesis of MF either
(Kanavaros et al, 1994; Dummer et al, 1995; Garatti et al, 1995).
Figure 4. Analysis of Bax expression in MF by
immunohistochemistry. Strong cytoplasmic staining of lymphoid cells
in the dermal in®ltrate.
Figure 3. Immunohistochemical staining with
anti-Fas antibody. (a) MF lesion of patient 5
with mutation and frameshift in exon 8 and
subsequent loss of death domain in Fas antigen
reveals staining of keratinocytes but not of
malignant lymphocytes in the epidermis and
dermis; (b) lichen planus shows strong membrane
staining of both keratinocytes and dermal
lymphocytes.
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Molecular analysis of p53, the most frequently mutated gene in
human malignancies, has been reported only four times in MF on
an overall number of 81 patients from patches to tumor-stage
disease, including cases transformed in large cell, more aggressive
lymphoma (CTCL) (Garatti et al, 1995; Li et al, 1998; Marrogi et al,
1999; McGregor et al, 1999). Relevant mutations have been found
in only 15 patients, a signi®cant number of them (six of 15)
occurring at dipyrimidine sites and resulting in C®T transitions
and one case in a CC®TT tandem base transition, a mutation
spectrum strikingly similar to that usually found in nonmelanoma
skin cancer and characteristic of DNA damage caused by ultraviolet
B radiation (McGregor et al, 1999). It is of interest that all reported
MF cases showing p53 mutations are from advanced, tumor stages,
or transformed aggressive large cell lymphoma, and that no patient
with patch- or plaque-stage disease displayed p53 mutation. Our
results on 41 patients with MF patches and plaques largely con®rm
these data. Accordingly, p53 alterations are unlikely to play a
signi®cant role in the pathogenesis of early MF. Data on p53
immunohistochemistry are more abundant. Overall, p53 staining of
lymphoid cells is infrequent in MF, and is largely limited to
advanced cases with either tumor stages or transformation in large
cell, more aggressive lymphoma (Kanavaros et al, 1994; Beylot-
Barry et al, 1995; de Misa et al, 1995; Garatti et al, 1995; Lauritzen et
al, 1995; McGregor et al, 1995; van Haselen et al, 1997; Kim et al,
1998; Li et al, 1998; Marrogi et al, 1999; McGregor et al, 1999) with
no clear relationship between molecular and immunohistochemical
data (Li et al, 1998). Our results are consistent with these ®ndings,
showing nuclear staining in two of 11 cases that do not display any
signi®cant p53 mutation. The high expression of p53 in epidermal
keratinocytes above MF dermal lesions with at least one antibody in
a signi®cant number of cases has not been previously reported and
could be explained by the production of stress-inducing cytokines
by neoplastic cells of the underlying dermal in®ltrate. The
reproducibility of this observation by others must be con®rmed
but this pattern was absent in all cases of eczema. If con®rmed,
these results could lead to a new element of discussion in the
evaluation of dermal lymphoid in®ltrates of uncertain nature.
In conclusion, we propose that an acquired defect in apoptosis,
in some cases through alterations of Fas antigen, in a subset of
activated T cells with cutaneous tropism, is involved in the
pathogenesis of early MF. This defect in the ability of tumor cells to
undergo apoptosis through the Fas/Fas ligand pathway could
explain the common resistance of MF to chemotherapy.
Conversely, two of the main regulators of apoptosis, p53 and
Bax, do not seem to be involved in defective apoptosis of MF cells.
Other molecules remain to be screened for functionally relevant
alterations in MF, e.g., Fas ligand and Caspases. The high
expression of p53 in supralesional keratinocytes remains to be
Figure 5. Analysis of p53 expression in MF.
(a) Nuclear staining of supra-lesional, normal-
appearing keratinocytes without staining of dermal
lymphocytes; (b) nuclear staining of dermal
lymphoid cells.
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con®rmed but, if so, could be an ancillary diagnostic tool in
ambiguous cases of cutaneous lymphoid in®ltrates.
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